These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 10401251)
1. [Treatment efficacy in acute intestinal infections, chronic diseases of the gastrointestinal tract and viral hepatitis B using large doses of Russian Bifidumbacterin-forte]. Gracheva NM; Shcherbakov IT; Avakov AA; Matsulevich TV Voen Med Zh; 1999 May; 320(5):51-7, 96. PubMed ID: 10401251 [TBL] [Abstract][Full Text] [Related]
2. [The microecological disorders in clinical pathology and their correction by bifidum-containing probiotics]. Vorob'ev AA; Bondarenko VM; Lykova EA; Grigor'ev AV; Matsulevich TM Vestn Ross Akad Med Nauk; 2004; (2):13-7. PubMed ID: 15101202 [TBL] [Abstract][Full Text] [Related]
3. [Use of loading doses of bifidumbacterin forte for treatment of patients with acute enteric infections]. Korviakova EP Zh Mikrobiol Epidemiol Immunobiol; 2000; (6):58-61. PubMed ID: 11210639 [TBL] [Abstract][Full Text] [Related]
4. [The development and clinical evaluation of the probiotic Bifidumbacterin forte]. Grigor'ev AV; Bondarenko VM; Abramov NA; Murashova AO; Feklisova LV; Chuprinina RP Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):92-6. PubMed ID: 9304342 [TBL] [Abstract][Full Text] [Related]
5. [Dysbacteriosis in patients with viral hepatitis]. Makos' RP; Dikiĭ BN; Zasukha GP Vrach Delo; 1988 Jul; (7):114-6. PubMed ID: 3188449 [No Abstract] [Full Text] [Related]
6. [Bacterial overgrowth syndrome in the small intestine: pathogenesis, clinical significance and therapy tactics]. Lykova EA; Bondarenko VM; Parfenov AI; Matsulevich TV Eksp Klin Gastroenterol; 2005; (6):51-7, 113. PubMed ID: 17378388 [TBL] [Abstract][Full Text] [Related]
7. [Disruption of microbiocenosis of the large intestine and the immune and interferon status in children with bacterial complications of acute viral infections of the respiratory tract and their correction by high doses of bifidumbacterin forte]. Lykova EA; Vorob'ev AA; Bokovoĭ AG; Pobedinskaia IN; Gevondian VS; Gevondian NM; Mitrokhin SD; Minaev VI; Dzis NB; Makkaveeva LF; Kovalev IV; Murashova AO; Bondarenko VM Antibiot Khimioter; 2000; 45(10):22-7. PubMed ID: 11212396 [TBL] [Abstract][Full Text] [Related]
8. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection. Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067 [TBL] [Abstract][Full Text] [Related]
10. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Prantera C; Scribano ML Curr Opin Gastroenterol; 2009 Jul; 25(4):329-33. PubMed ID: 19444096 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacotherapy of intestinal dysbacteriosis]. Chekman IS Lik Sprava; 2000; (7-8):6-11. PubMed ID: 16786636 [TBL] [Abstract][Full Text] [Related]
12. [The regulation of microecological disorders of the intestines in newborn infants with perinatal pathology using the new probiotic bifidumbacterin-forte]. Iakushenko MN; Tkhagapsoeva ZhM; Bondarenko VM Zh Mikrobiol Epidemiol Immunobiol; 1997; (6):18-22. PubMed ID: 9460858 [TBL] [Abstract][Full Text] [Related]